HCPLive Network

The Flu Vaccine is Safe in Children with Severe Egg Allergy

 
WEDNESDAY, Jan. 30 (HealthDay News) -- Children with a history of severe egg allergy, even anaphylaxis, can safely receive a single dose of trivalent seasonal influenza vaccine (TIV), according to a study published in the December issue of the Annals of Allergy, Asthma & Immunology.

Matthew J. Greenhawt, M.D., M.B.A., from the University of Michigan Health System in Ann Arbor, and colleagues randomly assigned 31 children with a history of a severe reaction after eating eggs (45.1 percent with a history of anaphylaxis) and an antibody response to egg to receive either 0.1 mL of influenza vaccine or saline followed by the remainder of the age-appropriate dose or the full dose after 30 minutes if there was no reaction. An additional retrospective study was conducted of 112 children (77.6 percent with a history of anaphylaxis) who had declined to participate in the trial and who had received either a split dose or a single dose of TIV.

The researchers found that none of the children in the randomized or retrospective studies developed an allergic reaction after receiving TIV. The use of split dosing was found to be unnecessary.

"TIV administration is safe even in children with histories of severe egg allergy," Greenhawt and colleagues conclude. "We believe these findings support further revision of the Advisory Committee on Immunization Practices guidelines to recommend that children with egg allergy of any severity, including anaphylaxis, should receive TIV as a single injection with a 30-minute observation period and do not require referral to an allergist for influenza vaccination."
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The immune system is the new focus of much work on traumatic brain injury (TBI). In a challenge to the paradigm that the blood brain barrier prevents harmful leukocytes from entering the brain, a Texas team tried to neutralize the impact of these cells. Peripheral lymphocytes are activated after TBI. They may then act as potential antigen presenting cells and get into the brain, causing cells there to degenerate.
Black women undergoing in vitro fertilization are only about half as likely as white women to become pregnant, and the racial disparity persists even when donor eggs are used. These findings are being presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
Hospital conversion to for-profit status is associated with improvements in financial margins, but has no effect on process quality metrics or mortality rates, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
More Reading